Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

A Randomized, Placebo-Controlled Pilot Study of Quetiapine-XR Monotherapy or Adjunctive Therapy to Antidepressant in Acute Major Depressive Disorder with Current Generalized Anxiety Disorder.

Li R, Wu R, Chen J, Kemp DE, Ren M, Conroy C, Chan P, Serrano MB, Ganocy SJ, Calabrese JR, Gao K.

Psychopharmacol Bull. 2016 Mar 1;46(1):8-23.

2.

Baseline disability and poor functioning in bipolar disorder predict worse outcomes: results from the Bipolar CHOICE study.

Deckersbach T, Nierenberg AA, McInnis MG, Salcedo S, Bernstein EE, Kemp DE, Shelton RC, McElroy SL, Sylvia LG, Kocsis JH, Bobo WV, Friedman ES, Singh V, Tohen M, Bowden CL, Ketter TA, Calabrese JR, Thase ME, Reilly-Harrington NA, Rabideau DJ, Kinrys G, Kamali M.

J Clin Psychiatry. 2016 Jan;77(1):100-8. doi: 10.4088/JCP.14m09210.

PMID:
26845265
3.

Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder.

McElroy SL, Kemp DE, Friedman ES, Reilly-Harrington NA, Sylvia LG, Calabrese JR, Rabideau DJ, Ketter TA, Thase ME, Singh V, Tohen M, Bowden CL, Bernstein EE, Brody BD, Deckersbach T, Kocsis JH, Kinrys G, Bobo WV, Kamali M, McInnis MG, Leon AC, Faraone S, Nierenberg AA, Shelton RC.

Acta Psychiatr Scand. 2015 Jun 26. doi: 10.1111/acps.12460. [Epub ahead of print]

4.

Managing the side effects associated with commonly used treatments for bipolar depression.

Kemp DE.

J Affect Disord. 2014 Dec;169 Suppl 1:S34-44. doi: 10.1016/S0165-0327(14)70007-2. Review.

5.

Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar I or II disorder: results from the Bipolar CHOICE study.

Bobo WV, Reilly-Harrington NA, Ketter TA, Brody BD, Kinrys G, Kemp DE, Shelton RC, McElroy SL, Sylvia LG, Kocsis JH, McInnis MG, Friedman ES, Singh V, Tohen M, Bowden CL, Deckersbach T, Calabrese JR, Thase ME, Nierenberg AA, Rabideau DJ, Schoenfeld DA, Faraone SV, Kamali M.

J Clin Psychopharmacol. 2015 Feb;35(1):68-74. doi: 10.1097/JCP.0000000000000257.

PMID:
25514063
6.

Disagreement between self-reported and clinician-ascertained suicidal ideation and its correlation with depression and anxiety severity in patients with major depressive disorder or bipolar disorder.

Gao K, Wu R, Wang Z, Ren M, Kemp DE, Chan PK, Conroy CM, Serrano MB, Ganocy SJ, Calabrese JR.

J Psychiatr Res. 2015 Jan;60:117-24. doi: 10.1016/j.jpsychires.2014.09.011. Epub 2014 Sep 19.

PMID:
25438963
7.

Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE).

Sylvia LG, Shelton RC, Kemp DE, Bernstein EE, Friedman ES, Brody BD, McElroy SL, Singh V, Tohen M, Bowden CL, Ketter TA, Deckersbach T, Thase ME, Reilly-Harrington NA, Nierenberg AA, Rabideau DJ, Kinrys G, Kocsis JH, Bobo WV, Kamali M, McInnis MG, Calabrese JR.

Bipolar Disord. 2015 Mar;17(2):212-23. doi: 10.1111/bdi.12243. Epub 2014 Aug 16.

8.

Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial.

Gao K, Wu R, Kemp DE, Chen J, Karberg E, Conroy C, Chan P, Ren M, Serrano MB, Ganocy SJ, Calabrese JR.

J Clin Psychiatry. 2014 Oct;75(10):1062-8. doi: 10.4088/JCP.13m08847.

PMID:
25007003
9.

Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial.

Bobo WV, Reilly-Harrington NA, Ketter TA, Brody BD, Kinrys G, Kemp DE, Shelton RC, McElroy SL, Sylvia LG, Kocsis JH, McInnis MG, Friedman ES, Singh V, Tohen M, Bowden CL, Deckersbach T, Calabrese JR, Thase ME, Nierenberg AA, Rabideau DJ, Schoenfeld DA, Faraone SV, Kamali M.

J Affect Disord. 2014 Jun;161:30-5. doi: 10.1016/j.jad.2014.02.046. Epub 2014 Mar 13.

10.

PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.

Kemp DE, Schinagle M, Gao K, Conroy C, Ganocy SJ, Ismail-Beigi F, Calabrese JR.

CNS Drugs. 2014 Jun;28(6):571-81. doi: 10.1007/s40263-014-0158-2.

11.

Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.

Kemp DE, Zhao J, Cazorla P, Landbloom RP, Mackle M, Snow-Adami L, Szegedi A.

J Clin Psychiatry. 2014 Mar;75(3):238-45. doi: 10.4088/JCP.12m08271.

PMID:
24499969
12.

Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.

Kemp DE, Correll CU, Tohen M, Delbello MP, Ganocy SJ, Findling RL, Chang K.

J Child Adolesc Psychopharmacol. 2013 Oct;23(8):522-30. doi: 10.1089/cap.2012.0099. Epub 2013 Oct 10.

13.

Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder.

Sylvia LG, Friedman ES, Kocsis JH, Bernstein EE, Brody BD, Kinrys G, Kemp DE, Shelton RC, McElroy SL, Bobo WV, Kamali M, McInnis MG, Tohen M, Bowden CL, Ketter TA, Deckersbach T, Calabrese JR, Thase ME, Reilly-Harrington NA, Singh V, Rabideau DJ, Nierenberg AA.

J Affect Disord. 2013 Nov;151(2):722-7. doi: 10.1016/j.jad.2013.07.031. Epub 2013 Aug 16.

PMID:
23993440
14.

General medical burden in bipolar disorder: findings from the LiTMUS comparative effectiveness trial.

Kemp DE, Sylvia LG, Calabrese JR, Nierenberg AA, Thase ME, Reilly-Harrington NA, Ostacher MJ, Leon AC, Ketter TA, Friedman ES, Bowden CL, Rabideau DJ, Pencina M, Iosifescu DV; LiTMUS Study Group.

Acta Psychiatr Scand. 2014 Jan;129(1):24-34. doi: 10.1111/acps.12101. Epub 2013 Mar 7.

15.

Should an assessment of Axis I comorbidity be included in the initial diagnostic assessment of mood disorders? Role of QIDS-16-SR total score in predicting number of Axis I comorbidity.

Gao K, Wang Z, Chen J, Kemp DE, Chan PK, Conroy CM, Serrano MB, Ganocy SJ, Calabrese JR.

J Affect Disord. 2013 Jun;148(2-3):256-64. doi: 10.1016/j.jad.2012.12.004. Epub 2012 Dec 28.

PMID:
23273550
16.

Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.

Kemp DE, De Hert M, Rahman Z, Fyans P, Eudicone JM, Marler SV, Baker RA, Carlson BX.

J Affect Disord. 2013 May 15;148(1):84-91. doi: 10.1016/j.jad.2012.11.054. Epub 2012 Dec 20.

PMID:
23261129
17.

Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar disorder.

Kemp DE, Gao K, Fein EB, Chan PK, Conroy C, Obral S, Ganocy SJ, Calabrese JR.

Bipolar Disord. 2012 Nov;14(7):780-9. doi: 10.1111/bdi.12013.

18.

Cardiometabolic Health in Bipolar Disorder.

Kemp DE, Fan J.

Psychiatr Ann. 2012 May 1;42(5):179-183. No abstract available.

19.

The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders.

McIntyre RS, Alsuwaidan M, Goldstein BI, Taylor VH, Schaffer A, Beaulieu S, Kemp DE; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force.

Ann Clin Psychiatry. 2012 Feb;24(1):69-81. Review.

PMID:
22303523
20.

Communication of potential benefits and harm to patients and payers in psychiatry: a review and commentary.

Wu R, Kemp DE, Sajatovic M, Zhao J, Calabrese JR, Gao K.

Clin Ther. 2011 Dec;33(12):B62-76. doi: 10.1016/j.clinthera.2011.11.013. Review.

PMID:
22177380

Supplemental Content

Support Center